Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. (OHSU/Kristyna Wentz-Graff). Members receive periodic email communication about events, programming, news and funding opportunities. These new drugs go through very rigorous testing in the laboratory and only if they meet certain criteria as promising anticancer agents, we bring them forward into the first phase of human clinical trials. Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. Study Purpose. Abstracts & Presentations. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. Claire Yoshida, M.S.N., A.C.N.S.-B.C., A.C.H.P.N. In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. Read More Contact Shivaani Kummar's Phone Number and Email Last Update 11/29/2022 2:55 AM Email s***@ohsu.edu Engage via Email Contact Number (***) ***-**** Engage via Phone Mobile Number (***) ***-**** Engage via Mobile HQ Phone Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Overall: 4.7 out of 5 2001-2023 OHSU. Administrative Coordinator, Margaret Rogers mollie hemingway face shivaani kummar ohsu email. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for This conversation is with Shivaani Kummar, MD (professor, oncology), who joined the Stanford faculty in January 2015. Clinical trials Drug development oncology. Shivaani Kummar. The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. Affiliated Hospitals Medical Group Practices Practice Location 3181 Sw Sam Jackson Park Rd Portland, Oregon 97239-3011 Map and Directions Phone: (503) 314-7168 Office Hours: Monday - Friday: 8:00 AM - 5:00 PM Saturday - Sunday: Closed condition, procedure, doctor name. Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. She currently practices at Oregon Health And Sciencs University Primary Care Clinic and is affiliated with Stanford Health Care. Shivaani Kummar, M.D., FACP Expertise Cancer Special focus Medical Oncology and Hematology Email this page Print this page About me Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. 2001-2022 Oregon Health & Science University. Palliative Care Administrative Assistant. Across OHSU, doctors and researchers are reimagining early disease detection. NPI Lookup NPI Database. Dr. Shivaani Kummar, MD is a medical oncology specialist in Portland, OR. Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. Today is a global celebration of giving an opportunity to support the causes that matter the most to you. Drukers approach to team science is incorporated throughout the institutes infrastructure. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. Username or E-mail. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. Faculty and staff recruitment information. OHSU Knight Cancer Institute is a national leader in cancer research and training and well-known for its ability to turn cancer research discoveries into new cancer treatments. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP The institute is involved with more than 400 clinical trials, including 113 early-phase trials. OHSU is an equal opportunity affirmative action institution. 2001-2022 Oregon Health & Science University. The new early-phase research unit completes this expansion in the building. OHSU Knight Cancer Institute leaders include some of the most distinguished doctors and scientists in the world. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. February 17, 2023. Give Now. Sort. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer Research', 'Montefiore Medical Center' 4 1 . The Knight Cancer Institute's Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. Post author By ; aleko lm137 manual Post date July 1, 2022; police clearance certificate in saudi arabia . Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. shivaani kummar ohsu email. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. By continuing you agree to the use of cookies. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. Nature reviews Drug discovery 9 (11), 843-856. Shivaani Kummar Aim: Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of. And to train and inspire the next generation of doctors and scientists. Dr. Shivaani Kummar has primarily specialised in Medical Oncology for over 31 years. Dr. I am humbled and inspired by the courage, grace and feeling of altruism that I find in each and every patient who chooses to participate in these trials. 2022 ASCO Annual Meeting - Poster Session . They have a high school-aged daughter and middle school-aged son. We are thrilled he is able to co-lead this new venture. OHSU is an equal opportunity affirmative action institution. For help with all referral needs and questions, visit Referring Physicians. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. Verified email at ohsu.edu. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Cited by. This center will be for the community, and we hope people will reach out to be a part of it. The Division of Hematology and Medical Oncology is headed by Shivaani Kummar, M.D., FACP and composed of many sections: Classical Hematology Community Oncology Hematologic Malignancies Palliative Care Portland VA Research Solid Tumor Stem Cell Transplantation Administration Section head Shivaani Kummar, M.D., FACP Philanthropy will allow us to expand the number of ongoing projects, including those focusing on rare tumors, as well as take on more pre- and post-doctoral students to train the next generation of cancer researchers. Dr. Kummar specializes in the care and treatment of patients with cancer. She co-leads a team of 90 faculty members and along with her husband, Sanjay Malhotra, PhD, is focused on discovering new therapies for cancer and giving more people access to safe, experimental cancer treatments. By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. Kummars remarkable accomplishments, combined with her ability to connect with people and her clear vision for how to grow the hematology-oncology division, made her our top candidate. Our ability to move these projects forward and to take on new projects is limited by the available resources. Email: trials@ohsu.edu Call: 503-494-1080 Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. Of that, $160 million was used for the Knight Cancer Research Building, which opened in 2018, and $40 million was used to build expanded capacity for clinical trial care in CHH2, which opened in 2019.